fig4

Figure 4. mIHC images of two representative patients showed differences in the TIME between the responder and non-responder groups. The fluorescence signal channels corresponding to each image are indicated in the bottom right corner of each figure. (A) TIME landscape of P7, who was evaluated as SD; (B) TIME landscape of P6, who achieved PR following the ECT regimen; (C) The proportion of YAP-1 positive cells and various immune cells in P7 and P6. The tumor parenchyma and stromal regions are divided based on PanCK staining. mIHC: Multi-immunohistochemistry; TIME: tumor immune microenvironment; SD: stable disease; PR: progression disease; ECT: atezolizumab plus etoposide/carboplatin.